Oncology

Pages we plan to refresh

• Carboplatin AUC Calculator: this is one of our highest-priority oncology calculator updates. The current “updated” page still asks users to specify race for its 2012 CKD-EPI option even though the page also documents the race-free 2021 CKD-EPI equation. We plan to make current race-free kidney assessment primary, clarify indexed versus non-indexed GFR/CrCl, measured GFR, obesity/body-weight assumptions, unstable renal function and protocol-specific dose caps.
• Absolute Neutrophil Count: we plan to keep the simple ANC equation while updating the older interpretation thresholds, febrile-neutropenia context, chemotherapy-specific treatment holds, growth-factor links and the fact that regimen-specific marrow criteria differ.
• BSA / BSA Multi-Calc: we plan to preserve the classic equations while clarifying that BSA is a dosing convention rather than a direct measure of drug clearance, efficacy or toxicity and that protocol-specific capping/weight guidance may apply.
• Oncology – Selected New Agents: this is a major long-term update project. The current table is dominated by 2014–2016-era monographs and older indications. We plan to rebuild it as a current class-, biomarker- and cancer-oriented oncology medication index with current DailyMed/FDA links instead of static “latest agent” claims.
• Prostate Cancer: the existing table centers on first-generation antiandrogens and LHRH agonists. We plan to rebuild it around contemporary androgen-receptor pathway inhibition, ADT strategy, PARP-targeted treatment, radiopharmaceuticals, chemotherapy, bone health and current disease-state sequencing.
• Anti-Emetics: we plan to rebuild this around emetogenic risk, current NK1/5-HT3 combinations, olanzapine, dexamethasone, breakthrough/refractory nausea, delayed CINV and current product labeling, removing obsolete chemotherapy-prophylaxis regimens.
• Oncology IV Dilution Monographs: we plan to preserve this as a core pharmacy resource while systematically verifying current formulations, concentrations, reconstitution, dilution, stability, infusion time, compatibility, hazardous-drug handling and products that have entered or left the market.
• Chemotherapy extravasation: the old landing page embedded a third-party summary. We plan to create a dedicated GlobalRPh extravasation center with agent-specific vesicant/irritant classification, aspiration, compress selection, antidotes, dexrazoxane, hyaluronidase, documentation and institution-policy verification.
• Febrile Neutropenia: the current high-risk page is from an older antimicrobial era. We plan to update risk stratification, empiric therapy, resistance risk, allergy, renal dosing, duration/de-escalation, diagnostic stewardship and oncology/ID collaboration.
• Colony-Stimulating Factors: we plan to update G-CSF agents and biosimilars, primary/secondary prophylaxis, regimen-level febrile-neutropenia risk and treatment-versus-prophylaxis distinctions.
• Tumor Lysis Syndrome: we plan to build a dedicated supportive-care page linking TLS risk, hydration, uric-acid strategy, allopurinol/rasburicase, electrolyte monitoring, kidney injury and high-risk hematologic therapies.
• Cell-therapy toxicity: we plan to create a dedicated CRS/ICANS/immune-effector toxicity center using current ASTCT terminology and product-specific guidance, with sepsis, neurologic toxicity and ICU cross-links.
• Cancer-associated thrombosis: we plan to connect Oncology more tightly with the Hematology anticoagulation center and current cancer-associated-VTE guidance rather than duplicating anticoagulant tables.
• Cancer pain: we plan to keep the advanced opioid and methadone tools but improve oncology-specific conversion cautions, incomplete cross-tolerance, organ dysfunction, neuropathic pain, palliative-care referral and survivorship pain.
• Clinical trials / approvals: we plan to use current NCI and FDA OCE sources as the dynamic reference layer rather than hard-coding rapidly changing “new drug” lists.
• Biomarker / precision oncology center: we plan to add a durable framework for molecular testing, tissue-agnostic therapy, liquid biopsy, MRD, companion diagnostics and the limitations of biomarker-only treatment decisions.
• Supportive care / survivorship: we plan to expand nutrition, fatigue, neuropathy, bone health, fertility/sexual function, cognition, cardiotoxicity, psychosocial care and survivorship monitoring using current ASCO and disease-specific guidance.